Securities code: 000710 securities abbreviation: Berry Genomics Co.Ltd(000710) Announcement No.: 2022-005 Berry Genomics Co.Ltd(000710)
Announcement on the progress of more than half of the implementation time of the share reduction plan of shareholders holding more than 5%
Tianjin junruiqi equity investment partnership (limited partnership), a shareholder holding more than 5%, guarantees that the information provided to the company is true, accurate and complete without false records, misleading statements or major omissions. The company and all members of the board of directors guarantee that the contents of the announcement are consistent with the information provided by the information disclosure obligor. Special tips:
Berry Genomics Co.Ltd(000710) (hereinafter referred to as “the company”) disclosed the pre disclosure announcement on the reduction of shares held by shareholders holding more than 5% (Announcement No.: 2021-074) on November 4, 2021: Tianjin junruiqi equity investment partnership (limited partnership) (hereinafter referred to as “junruiqi”) plans to start from November 25, 2021 to February 24, 2022 During the period, the company reduced no more than 3546000 shares (accounting for about 1.00% of the total share capital of the company) in the form of centralized bidding transaction, and planned to reduce no more than 7092100 shares (accounting for about 2.00% of the total share capital of the company) in the form of block transaction from November 9, 2021 to February 8, 2022, The above reduction shall not exceed 10638100 shares in total (accounting for about 3.00% of the total share capital of the company) (hereinafter referred to as the “reduction plan”). Recently, the company received the notification letter on the progress of share reduction from Tianjin junruiqi equity investment partnership (limited partnership): junruiqi has reduced 3640000 shares of the company (accounting for about 1.03% of the total share capital of the company) during the period of this reduction plan. The implementation time of this reduction plan is more than half, and this reduction plan has not been completed.
1、 Shareholder reduction
1. Share reduction by shareholders
Number and proportion of shares reduced in the reduction price area
Name of shareholders reduction method during the reduction period (yuan / share) (share) accounting for the total share capital accounting for the total number of the reduction plan
Centralized bidding 2021.11.26 – 20.31-24.46 3200000 0.9024% 30.0806% junruiqi transaction 2021.12.21
Block transaction 2021.11.30-2 20.08-21.35 440000 0.1241% 4.1361% 021.12.2
Total — 3640000 1.0265% 34.2167%
Junruiqi’s share reduction plan comes from the new shares of the company obtained from the subscription of Beirui Hekang’s shares held in the transaction of issuing shares to purchase 100% equity of Beijing Beirui Hekang Biotechnology Co., Ltd. (hereinafter referred to as “Beirui Hekang”) and major asset restructuring, which are tradable shares with unlimited sales conditions.
2. Shareholding before and after the implementation of this reduction
Shares held by shareholders before this reduction and shares held after this reduction
Name share nature share number in total share capital share number in total share capital (share) (%) (share) (%)
Total shares held 17730261 5.0000 14090261 3.9735
Junruiqi, including: shares with unlimited sales conditions 17730261 5.0000 14090261 3.9735
Shares with limited sales conditions —-
2、 Other relevant instructions
1. The company has pre disclosed junruiqi’s share reduction plan and disclosed the progress announcement of its share reduction of 1%, and there are no violations (for details, see pre disclosure announcement on share reduction by shareholders holding more than 5% (Announcement No.: 2021-074) and announcement on share reduction by shareholders holding more than 5% (Announcement No.: 2021-076)).
2. The shares held by junruiqi are not prohibited from exercising voting rights. This reduction strictly complies with the company law, the stock listing rules of Shenzhen Stock Exchange, the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange, the detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of listed companies of Shenzhen Stock Exchange and other relevant laws There is no violation of regulations, rules and business rules on share transfer.
3. Junruiqi’s reduction is consistent with the disclosed reduction plan and commitments, and there is no violation.
4. Junruiqi is not the controlling shareholder and actual controller of the company. This reduction will not change the control right of the company and will not affect the corporate governance structure and sustainable production and operation.
5. After this reduction, junruiqi will no longer be a shareholder holding more than 5% of the company’s shares, but its shares are still specific shares and will still comply with the restrictive provisions on changes in relevant shares.
6. Junruiqi will decide whether to continue to implement the reduction plan according to the market and stock price in the future, which is still uncertain. The company will continue to pay attention to the implementation progress of its share reduction plan and timely fulfill the obligation of information disclosure. Please pay attention to the investment risks.
It is hereby announced.
Berry Genomics Co.Ltd(000710) board of directors January 11, 2022
